This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ASM journals Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rastogi, N. Articles by Casal, M. Search for Related Content PubMed PubMed Citation Articles by Rastogi, N. Articles by Casal, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 05 1995, 1162-1165, Vol 39, No. 5
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

In vitro activity of roxithromycin against the Mycobacterium tuberculosis complex

N Rastogi, KS Goh, P Ruiz and M Casal
Unite de la Tuberculose & des Mycobacteries, Institut Pasteur, Guadeloupe, French West Indies.

Roxithromycin has recently been shown to possess significant in vitro activity against a variety of atypical mycobacteria such as the M. avium complex, M. scrofulaceum, M. szulgai, M. malmoense, M. xenopi, M. marinum, and M. kansasii and rare pathogens like M. chelonei and M. fortuitum. In the present investigation, screening of its in vitro activity was further extended by testing it against 34 strains belonging to the M. tuberculosis complex (including M. tuberculosis, M. africanum, M. bovis, and M. bovis BCG). The MICs were determined by the radiometric BACTEC 460-TB methodology at pHs of both 6.8 and 7.4, as well as with 7H10 agar medium by the 1% proportion method. With the exception of M. bovis BCG (MIC ranges, 0.5 to 4 micrograms/ml at pH 6.8 and 0.25 to 2 micrograms/ml at pH 7.4), MICs for all of the isolates were significantly greater (MIC ranges, 32 to > 64 micrograms/ml at pH 6.8 and 16 to > 32 micrograms/ml at pH 7.4) than those reported previously for atypical mycobacteria. Roxithromycin MICs of 64 or > 64 micrograms/ml for all of the M. tuberculosis isolates screened were found by the 7H10 agar medium method. Roxithromycin, however, showed a pH-dependent bactericidal effect against M. tuberculosis because the drug was relatively more active when it was used at pH 7.4 than when it was used at pH 6.8. We conclude that roxithromycin per se is not a drug of choice for the treatment of M. tuberculosis infection or disease; however, considering its pharmacokinetics, eventual anti-tubercle bacillus activity in an in vivo system cannot yet be excluded.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

• Dawes, S. S., Warner, D. F., Tsenova, L., Timm, J., McKinney, J. D., Kaplan, G., Rubin, H., Mizrahi, V. (2003). Ribonucleotide Reduction in Mycobacterium tuberculosis: Function and Expression of Genes Encoding Class Ib and Class II Ribonucleotide Reductases. Infect. Immun. 71: 6124-6131 [Abstract] [Full Text]  
• Rastogi, N., Goh, K. S., Berchel, M., Bryskier, A. (2000). Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. J Antimicrob Chemother 46: 565-570 [Abstract] [Full Text]